Paul J Grant1,2, M Todd Greene1,2, Vineet Chopra1,2,3, Steven J Bernstein1,2,3, Timothy P Hofer1,3, Scott A Flanders1,2. 1. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI. 2. Michigan Hospital Medicine Safety Consortium. 3. Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI.
Abstract
BACKGROUND: The optimal approach to assess risk of venous thromboembolism in hospitalized medical patients is unknown. We examined how well the Caprini risk assessment model predicts venous thromboembolism in hospitalized medical patients. METHODS: Between January 2011 and March 2014, venous thromboembolism events and risk factors were collected from non-intensive care unit medical patients hospitalized in facilities across Michigan. After calculation of the Caprini score for each patient, mixed logistic spline regression was used to determine the predicted probabilities of 90-day venous thromboembolism by receipt of pharmacologic prophylaxis across the Caprini risk continuum. RESULTS: A total of 670 (1.05%) of 63,548 eligible patients experienced a venous thromboembolism event within 90 days of hospital admission. The mean Caprini risk score was 4.94 (range, 0-28). Predictive modeling revealed a consistent linear increase in venous thromboembolism for Caprini scores between 1 and 10; estimates beyond a score of 10 were unstable. Receipt of pharmacologic prophylaxis resulted in a modest decrease in venous thromboembolism risk (odds ratio, 0.85; 95% confidence interval, 0.72-0.99; P = .04). However, the low overall incidence of venous thromboembolism led to large estimates of numbers needed to treat to prevent a single venous thromboembolism event. A Caprini cut-point demonstrating clear benefit of prophylaxis was not detected. CONCLUSIONS: Although a linear association between the Caprini risk assessment model and the risk of venous thromboembolism was noted, an extremely low incidence of venous thromboembolism events in non-intensive care unit medical patients was observed. The Caprini risk assessment model was unable to identify a subset of medical patients who benefit from pharmacologic prophylaxis.
BACKGROUND: The optimal approach to assess risk of venous thromboembolism in hospitalized medical patients is unknown. We examined how well the Caprini risk assessment model predicts venous thromboembolism in hospitalized medical patients. METHODS: Between January 2011 and March 2014, venous thromboembolism events and risk factors were collected from non-intensive care unit medical patients hospitalized in facilities across Michigan. After calculation of the Caprini score for each patient, mixed logistic spline regression was used to determine the predicted probabilities of 90-day venous thromboembolism by receipt of pharmacologic prophylaxis across the Caprini risk continuum. RESULTS: A total of 670 (1.05%) of 63,548 eligible patients experienced a venous thromboembolism event within 90 days of hospital admission. The mean Caprini risk score was 4.94 (range, 0-28). Predictive modeling revealed a consistent linear increase in venous thromboembolism for Caprini scores between 1 and 10; estimates beyond a score of 10 were unstable. Receipt of pharmacologic prophylaxis resulted in a modest decrease in venous thromboembolism risk (odds ratio, 0.85; 95% confidence interval, 0.72-0.99; P = .04). However, the low overall incidence of venous thromboembolism led to large estimates of numbers needed to treat to prevent a single venous thromboembolism event. A Caprini cut-point demonstrating clear benefit of prophylaxis was not detected. CONCLUSIONS: Although a linear association between the Caprini risk assessment model and the risk of venous thromboembolism was noted, an extremely low incidence of venous thromboembolism events in non-intensive care unit medical patients was observed. The Caprini risk assessment model was unable to identify a subset of medical patients who benefit from pharmacologic prophylaxis.
Authors: Alexander T Cohen; Raza Alikhan; Juan I Arcelus; Jean-François Bergmann; Sylvia Haas; Geno J Merli; Alex C Spyropoulos; Victor F Tapson; Alexander G G Turpie Journal: Thromb Haemost Date: 2005-10 Impact factor: 5.249
Authors: S Barbar; F Noventa; V Rossetto; A Ferrari; B Brandolin; M Perlati; E De Bon; D Tormene; A Pagnan; P Prandoni Journal: J Thromb Haemost Date: 2010-11 Impact factor: 5.824
Authors: Scott C Woller; Scott M Stevens; Jason P Jones; James F Lloyd; R Scott Evans; Valerie T Aston; C Gregory Elliott Journal: Am J Med Date: 2011-10 Impact factor: 4.965
Authors: Alex C Spyropoulos; Frederick A Anderson; Gordon FitzGerald; Herve Decousus; Mario Pini; Beng H Chong; Rainer B Zotz; Jean-François Bergmann; Victor Tapson; James B Froehlich; Manuel Monreal; Geno J Merli; Ricardo Pavanello; Alexander G G Turpie; Mashio Nakamura; Franco Piovella; Ajay K Kakkar; Frederick A Spencer Journal: Chest Date: 2011-03-24 Impact factor: 9.410
Authors: Nils Kucher; Sophia Koo; Rene Quiroz; Joshua M Cooper; Marilyn D Paterno; Boris Soukonnikov; Samuel Z Goldhaber Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell Journal: Chest Date: 2008-06 Impact factor: 9.410
Authors: Christopher J Pannucci; Kory I Fleming; Thomas K Varghese; John Stringham; Lyen C Huang; T Bartley Pickron; Ann Marie Prazak; Corinne Bertolaccini; Arash Momeni Journal: Ann Surg Date: 2020-10-19 Impact factor: 12.969
Authors: Andrea J Darzi; Samer G Karam; Rana Charide; Itziar Etxeandia-Ikobaltzeta; Mary Cushman; Michael K Gould; Lawrence Mbuagbaw; Frederick A Spencer; Alex C Spyropoulos; Michael B Streiff; Scott Woller; Neil A Zakai; Federico Germini; Marta Rigoni; Arnav Agarwal; Rami Z Morsi; Alfonso Iorio; Elie A Akl; Holger J Schünemann Journal: Blood Date: 2020-05-14 Impact factor: 22.113
Authors: Luis E De León; Carlos E Bravo-Iñiguez; Sam Fox; Jeffrey Tarascio; Samuel Freyaldenhoven; Moshe Lapidot; Michael T Jaklitsch; Raphael Bueno Journal: J Thorac Cardiovasc Surg Date: 2020-01-30 Impact factor: 5.209
Authors: Andrea J Darzi; Samer G Karam; Frederick A Spencer; Alex C Spyropoulos; Lawrence Mbuagbaw; Scott C Woller; Neil A Zakai; Michael B Streiff; Michael K Gould; Mary Cushman; Rana Charide; Itziar Etxeandia-Ikobaltzeta; Federico Germini; Marta Rigoni; Arnav Agarwal; Rami Z Morsi; Elie A Akl; Alfonso Iorio; Holger J Schünemann Journal: Blood Adv Date: 2020-06-23